[24] Fruchart JC, Duriez P. Mode of action of fibrates in the regulation of
triglyceride and HDL-cholesterol metabolism. Drugs Today 2006;42:
39 – 64.
[25] Deeg MA, Buse JB, Goldberg RB, Kendall DM, Zagar AJ, Jacober
SJ, et al. Pioglitazone and rosiglitazone have different effects on
serum lipoprotein particle concentrations and sizes in patients with
type 2 diabetes and dyslipidemia. Diabetes Care 2007;30:2458– 64.
[26] Gastaldelli A, Ferrannini E, Miyazaki Y, Matsuda M, Mari A, DeFronzo
RA. Thiazolidinediones improve beta-cell function in type 2 diabetic
patients. Am J Physiol Endocrinol Metab 2007;292:E871– 83.
[27] Miyazaki Y, He H, Mandarino LJ, DeFronzo RA. Rosiglitazone
improves downstream insulin receptor signaling in type 2 diabetic
patients. Diabetes 2003;52:1943–50.
[28] Parulkar AA, Pendergrass ML, Granda-Ayala R, Lee TR, Fonseca
VA. Nonhypoglycemic effects of thiazolidinediones. Ann Intern Med
2001;134:61–71.
[29] Berthou L, Duverger N, Emmanuel F, Langouet S, Auwerx J, Guil-
louzo A, et al. Opposite regulation of human versus mouse apoli-
poprotein A-I by fibrates in human apolipoprotein A-I transgenic
mice. J Clin Invest 1996;97:2408 –16.
[30] Staels B, van Tol A, Andreu T, Auwerx J. Fibrates influence the
expression of genes involved in lipoprotein metabolism in a tissue-
selective manner in the rat. Arterioscler Thromb 1992;12:286–94.
[31] Olefsky JM. Treatment of insulin resistance with peroxisome proliferator-
activated receptor gamma agonists. J Clin Invest 2000;106:467–72.
[32] Kramer D, Shapiro R, Adler A, Bush E, Rondinone CM. Insulin-
sensitizing effect of rosiglitazone (BRL-49653) by regulation of glu-
cose transporters in muscle and fat of Zucker rats. Metab Clin Exp
2001;50:1294 –300.
[33] Kim H, Haluzik M, Gavrilova O, Yakar S, Portas J, Sun H, et al.
Thiazolidinediones improve insulin sensitivity in adipose tissue and
reduce the hyperlipidaemia without affecting the hyperglycaemia in a
transgenic model of type 2 diabetes. Diabetologia 2004;47:2215–25.
[34] Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral
edema, and type 2 diabetes: incidence, pathophysiology, and clinical
implications. Endocr Pract 2003;9:406–16.
[35] Fuchtenbusch M, Standl E, Schatz H. Clinical efficacy of new thia-
zolidinediones and glinides in the treatment of type 2 diabetes mel-
litus. Exp Clin Endocrinol Diabetes 2000;108:151– 63.
[36] Singh S, Loke YK, Furberg CD. Long-term risk of cardiovascular events
with rosiglitazone: a meta-analysis. JAMA 2007;298:1189 –95.
[37] Carley AN, Semeniuk LM, Shimoni Y, Aasum E, Larsen TS, Berger
JP, et al. Treatment of type 2 diabetic db/db mice with a novel
PPARgamma agonist improves cardiac metabolism but not contrac-
tile function. Am J Physiol Endocrinol Metab 2004;286:E449–55.
[38] Chang CH, McNamara LA, Wu MS, Muise ES, Tan Y, Wood HB, et
al. A novel selective peroxisome proliferator-activator receptor-
gamma modulator-SPPARgammaM5 improves insulin sensitivity
with diminished adverse cardiovascular effects. Eur J Pharmacol
2008;584:192–201.
[39] Wu L, Wang R, De Champlain J, Wilson TW. Beneficial and dele-
terious effects of rosiglitazone on hypertension development in spon-
taneously hypertensive rats. Am J Hypertens 2004;17:749–56.
[40] Sopasakis VR, Sandqvist M, Gustafson B, Hammarstedt A, Schmelz
M, Yang X, et al. High local concentrations and effects on differen-
tiation implicate interleukin-6 as a paracrine regulator. Obes Res
2004;12:454 – 60.
[41] Le Lay S, Krief S, Farnier C, Lefrere I, Le Liepvre X, Bazin R, et al.
Cholesterol, a cell size-dependent signal that regulates glucose me-
tabolism and gene expression in adipocytes. J Biol Chem 2001;276:
16904 –10.
[42] Krotkiewski M, Bjorntorp P, Sjostrom L, Smith U. Impact of obesity
on metabolism in men and women. Importance of regional adipose
tissue distribution. J Clin Invest 1983;72:1150 – 62.
[43] Weyer C, Foley JE, Bogardus C, Tataranni PA, Pratley RE. Enlarged
subcutaneous abdominal adipocyte size, but not obesity itself, pre-
dicts type II diabetes independent of insulin resistance. Diabetologia
2000;43:1498 –506.
[44] Powell K. Obesity: the two faces of fat. Nature 2007;447:525–7.
[45] Yang X, Smith U. Adipose tissue distribution and risk of metabolic
disease: does thiazolidinedione-induced adipose tissue redistribution
provide a clue to the answer? Diabetologia 2007;50:1127–39.
[46] Baumann H, Gauldie J. Regulation of hepatic acute phase plasma
protein genes by hepatocyte stimulating factors and other mediators
of inflammation. Mol Biol Med 1990;7:147–59.
[47] Fernandez-Real JM, Vayreda M, Richart C, Gutierrez C, Broch M,
Vendrell J, et al. Circulating interleukin 6 levels, blood pressure, and
insulin sensitivity in apparently healthy men and women. J Clin
Endocrinol Metabol 2001;86:1154 –9.
[48] Tritos NA, Mantzoros CS. Leptin: its role in obesity and beyond.
Diabetologia 1997;40:1371–9.
[49] Lundgren M, Buren J, Ruge T, Myrnas T, Eriksson JW. Glucocorti-
coids down-regulate glucose uptake capacity and insulin-signaling
proteins in omental but not subcutaneous human adipocytes. J Clin
Endocrinol Metabol 2004;89:2989 –97.
[50] Virtanen KA, Lonnroth P, Parkkola R, Peltoniemi P, Asola M, Vil-
janen T, et al. Glucose uptake and perfusion in subcutaneous and
visceral adipose tissue during insulin stimulation in nonobese and
obese humans. J Clin Endocrinol Metabol 2002;87:3902–10.
[51] Cinti S, Mitchell G, Barbatelli G, Murano I, Ceresi E, Faloia E, et al.
Adipocyte death defines macrophage localization and function in adipose
tissue of obese mice and humans. J Lipid Res 2005;46:2347–55.
[52] Carmona MC, Louche K, Nibbelink M, Prunet B, Bross A, Desbazeille
M, et al. Fenofibrate prevents Rosiglitazone-induced body weight gain in
ob/ob mice. Int J Obes Relat Metab Disord 2005;29:864 –71.
[53] Ferreira AVM, Parreira GG, Green A, Botion LM. Effects of feno-
fibrate on lipid metabolism in adipose tissue of rats. Metab Clin Exp
2006;55:731–5.
[54] Fredenrich A, Grimaldi PA. PPAR delta: an uncompletely known
nuclear receptor. Diabetes Metabol 2005;31:23–7.
[55] Peters JM, Aoyama T, Burns AM, Gonzalez FJ. Bezafibrate is a dual
ligand for PPARalpha and PPARbeta: studies using null mice. Bioch
Biophys Acta 2003;1632:80 –9.
[56] Kjorholt C, Akerfeldt MC, Biden TJ, Laybutt DR. Chronic hypergly-
cemia, independent of plasma lipid levels, is sufficient for the loss of
beta-cell differentiation and secretory function in the db/db mouse
model of diabetes. Diabetes 2005;54:2755– 63.
[57] Yoshikawa T, Toda K, Nemoto Y, Ono M, Iwasaki S, Maeda T, et al.
Aromatase-deficient (ArKO) mice are retrieved from severe hepatic
steatosis by peroxisome proliferator administration. Hepatol Res
2002;22:278 – 87.
[58] Takeda K, Toda K, Saibara T, Nakagawa M, Saika K, Onishi T, et al.
Progressive development of insulin resistance phenotype in male
mice with complete aromatase (CYP19) deficiency. J Endocrinol
2003;176:237– 46.
[59] Choi KC, Ryu OH, Lee KW, Kim HY, Seo JA, Kim SG, et al. Effect
of PPAR-alpha and -gamma agonist on the expression of visfatin,
adiponectin, and TNF-alpha in visceral fat of OLETF rats. Biochem
Biophys Res Commun 2005;336:747–53.
[60] Tsuboyama-Kasaoka N, Takahashi M, Kim H, Ezaki O. Up-regulation
of liver uncoupling protein-2 mRNA by either fish oil feeding or
fibrate administration in mice. Biochem Biophys Res Commun 1999;
257:879 – 85.
[61] Koh EH, Kim MS, Park JY, Kim HS, Youn JY, Park HS, et al.
Peroxisome proliferator-activated receptor (PPAR)-alpha activation
prevents diabetes in OLETF rats: comparison with PPAR-gamma
activation. Diabetes 2003;52:2331–7.
[62] Mancini FP, Lanni A, Sabatino L, Moreno M, Giannino A, Contaldo
F, et al. Fenofibrate prevents and reduces body weight gain and
adiposity in diet-induced obese rats. FEBS Lett 2001;491:154– 8.
827C. Fernandes-Santos et al. / Nutrition 25 (2009) 818 – 827